Previous close | 47.69 |
Open | 47.56 |
Bid | 39.94 x 100 |
Ask | 46.72 x 200 |
Day's range | 46.31 - 47.57 |
52-week range | 42.63 - 56.26 |
Volume | |
Avg. volume | 1,929,487 |
Market cap | 118.154B |
Beta (5Y monthly) | 0.45 |
PE ratio (TTM) | 20.35 |
EPS (TTM) | 2.29 |
Earnings date | N/A |
Forward dividend & yield | 2.04 (4.37%) |
Ex-dividend date | 09 May 2024 |
1y target est | 59.12 |
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.